CL2007002293A1 - Compuestos derivados de 4-(5-oxo-pirrolidin-amino)-benzonitrilo, moduladores de los receptores de progesterona; composicion farmaceutica; y uso para tratar endometriosis, fibroma uterino, dismenorrea, menorragia, parto prematuro, esterilidad y para p - Google Patents

Compuestos derivados de 4-(5-oxo-pirrolidin-amino)-benzonitrilo, moduladores de los receptores de progesterona; composicion farmaceutica; y uso para tratar endometriosis, fibroma uterino, dismenorrea, menorragia, parto prematuro, esterilidad y para p

Info

Publication number
CL2007002293A1
CL2007002293A1 CL200702293A CL2007002293A CL2007002293A1 CL 2007002293 A1 CL2007002293 A1 CL 2007002293A1 CL 200702293 A CL200702293 A CL 200702293A CL 2007002293 A CL2007002293 A CL 2007002293A CL 2007002293 A1 CL2007002293 A1 CL 2007002293A1
Authority
CL
Chile
Prior art keywords
menorragy
dismenorrea
pirrolidin
progesterone
benzonitrile
Prior art date
Application number
CL200702293A
Other languages
English (en)
Inventor
David G Thompson Scot Washburn
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CL2007002293A1 publication Critical patent/CL2007002293A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL200702293A 2006-08-09 2007-08-07 Compuestos derivados de 4-(5-oxo-pirrolidin-amino)-benzonitrilo, moduladores de los receptores de progesterona; composicion farmaceutica; y uso para tratar endometriosis, fibroma uterino, dismenorrea, menorragia, parto prematuro, esterilidad y para p CL2007002293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82184106P 2006-08-09 2006-08-09

Publications (1)

Publication Number Publication Date
CL2007002293A1 true CL2007002293A1 (es) 2008-02-22

Family

ID=39082895

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702293A CL2007002293A1 (es) 2006-08-09 2007-08-07 Compuestos derivados de 4-(5-oxo-pirrolidin-amino)-benzonitrilo, moduladores de los receptores de progesterona; composicion farmaceutica; y uso para tratar endometriosis, fibroma uterino, dismenorrea, menorragia, parto prematuro, esterilidad y para p

Country Status (16)

Country Link
US (2) US20100210706A1 (es)
EP (1) EP2049104B1 (es)
JP (1) JP5205379B2 (es)
KR (1) KR20090035695A (es)
CN (1) CN101522190A (es)
AR (1) AR062233A1 (es)
AU (1) AU2007284161A1 (es)
BR (1) BRPI0715355A2 (es)
CA (1) CA2660397A1 (es)
CL (1) CL2007002293A1 (es)
EA (1) EA200970189A1 (es)
ES (1) ES2393632T3 (es)
MX (1) MX2009001442A (es)
PE (1) PE20081313A1 (es)
TW (1) TW200825051A (es)
WO (1) WO2008021796A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2607089T3 (es) 2010-09-03 2017-03-29 Lg Life Sciences Ltd Método de producción de un compuesto intermedio para sintetizar un medicamento
KR101185583B1 (ko) * 2011-12-27 2012-09-24 김영재 매듭짓는 작업이 필요 없는 봉합사 및 이를 포함하는 키트
TW201534586A (zh) * 2013-06-11 2015-09-16 Orion Corp 新穎cyp17抑制劑/抗雄激素劑

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959482A (en) * 1988-09-26 1990-09-25 Biofor, Ltd. Pyrrolidinone compounds and pharamaceutical compositions containing same
GB9113031D0 (en) 1991-06-17 1991-08-07 Smithkline Beecham Plc Compounds
WO2004110978A2 (en) * 2003-06-10 2004-12-23 Smithkline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
JP2007500245A (ja) * 2003-06-10 2007-01-11 スミスクライン ビーチャム コーポレーション 化合物
ES2523017T3 (es) 2004-03-03 2014-11-20 Glaxosmithkline Llc Derivados de anilina como moduladores selectivos de los receptores de andrógenos
JP2008515998A (ja) * 2004-10-13 2008-05-15 スミスクライン ビーチャム コーポレーション 化合物
EP1871379A4 (en) 2005-04-15 2010-06-02 Glaxosmithkline Llc CYANOARYLAMINE
EP1888512A2 (en) * 2005-06-06 2008-02-20 Smithkline Beecham Corporation Chemical compounds
JP2009518313A (ja) * 2005-11-30 2009-05-07 スミスクライン・ビーチャム・コーポレイション ピロリジンアニリン
EP2094269A1 (en) 2006-12-19 2009-09-02 Smithkline Beecham Corporation Pyrrolidinanilines

Also Published As

Publication number Publication date
EP2049104B1 (en) 2012-09-19
JP2010500366A (ja) 2010-01-07
PE20081313A1 (es) 2008-11-15
MX2009001442A (es) 2009-02-18
EP2049104A2 (en) 2009-04-22
US20080039517A1 (en) 2008-02-14
KR20090035695A (ko) 2009-04-10
WO2008021796A2 (en) 2008-02-21
ES2393632T3 (es) 2012-12-26
EA200970189A1 (ru) 2009-08-28
JP5205379B2 (ja) 2013-06-05
AR062233A1 (es) 2008-10-22
BRPI0715355A2 (pt) 2013-06-18
EP2049104A4 (en) 2009-09-09
AU2007284161A1 (en) 2008-02-21
CN101522190A (zh) 2009-09-02
CA2660397A1 (en) 2008-02-21
US20100210706A1 (en) 2010-08-19
US7816395B2 (en) 2010-10-19
TW200825051A (en) 2008-06-16
WO2008021796A3 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
CL2007002199A1 (es) Compuestos derivados de sulfonil amida, moduladores del receptor cb2; composicion farmaceutica; y su uso para tratar enfermedades inflamatorias y autoinmune.
DE602007006040D1 (de) Hemmstoffe des progesteron-rezeptors
BRPI0712516A2 (pt) compostos, composições farmacêuticas, antagonista receptor de a2b, método para uso terapêutico e/ou tratamento profilático e uso de antagonista receptor de a2b
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
CL2011000570A1 (es) Compuestos derivados de 3-(4-ciano-fenil)-pirazol-5-carboxamida, moduladores del receptor de progesterona; composicion farmaceutica; y su uso para el tratamiento de endometriosis, fibromiomas uterinos, dismenorrea primaria o secundaria, entre otras.
CL2007003832A1 (es) Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
ECSP077233A (es) Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
SV2010003718A (es) Inhibidores de bace
CL2011000087A1 (es) Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad.
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
CL2012001072A1 (es) Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas.
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
UY30610A1 (es) Moduladores de mglur5
GT200700064A (es) Agonistas de ep2
DOP2011000272A (es) Derivados de pirazolo usados como antagonistas receptores de ccr4
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
CL2007002970A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
CL2009001298A1 (es) Compuestos derivados de n-ciclohexil-2-fenoxinicotinamida; composición farmcéutica que los comprende; combinación farmacéutica que los comprende; y su uso para tratar una enfermedad mediada por la pde4.
BRPI0916622A2 (pt) derivados de piperazina usados como moduladores de canal de cálcio cav2,2
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина